MAGE-A Antibody (6C1): sc-20034
- MAGE-A Antibody (6C1) is a mouse monoclonal IgG2a κ MAGE-A antibody, cited in 57 publications, provided at 200 µg/ml
- raised against a prokaryotic recombinant fusion protein corresponding to the full length MAGE-A11
- MAGE-A Antibody (6C1) is recommended for detection of MAGE-A1, MAGE-A2, MAGE-A3, MAGE-A4, MAGE-A6, MAGE-A10 and MAGE-A12 of mouse, rat and human origin by WB, IP, IF, IHC(P) and ELISA
- Anti-MAGE-A Antibody (6C1) is available conjugated to agarose for IP; HRP for WB, IHC(P) and ELISA; and to either phycoerythrin or FITC for IF, IHC(P) and FCM
- also available conjugated to Alexa Fluor® 488, Alexa Fluor® 546, Alexa Fluor® 594 or Alexa Fluor® 647 for WB (RGB), IF, IHC(P) and FCM, and for use with RGB fluorescent imaging systems, such as iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- also available conjugated to Alexa Fluor® 680 or Alexa Fluor® 790 for WB (NIR), IF and FCM; for use with Near-Infrared (NIR) detection systems, such as LI-COR®Odyssey®, iBright™ FL1000, FluorChem™, Typhoon, Azure and other comparable systems
- m-IgGκ BP-HRP is the preferred secondary detection reagent for MAGE-A Antibody (6C1) for WB and IHC(P) applications. This reagent is now offered in a bundle with MAGE-A Antibody (6C1) (see ordering information below). For additional m-IgGκ BP conjugates see our complete list of Mouse IgG Binding Proteins.
MAGE-A Antibody (6C1) is a mouse monoclonal IgG2a kappa light chain antibody that detects MAGE-A protein in mouse, rat, and human samples through western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). Anti-MAGE-A antibody (6C1) comes in non-conjugated form and various conjugates, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® options. The melanoma-associated antigen (MAGE) family plays a vital role in cancer immunotherapy due to unique expression patterns; these antigens appear primarily in tumors and are recognized by cytotoxic T lymphocytes, making them promising therapeutic targets. MAGE-A proteins concentrate in tumor cell nuclei, suggesting involvement in gene expression regulation and cell cycle progression, which may influence tumor growth and survival. MAGE genes show restricted expression, appearing mainly in tumors except for normal testis and placenta tissue, highlighting their value as cancer biomarkers. Nuclear localization and function of MAGE-A proteins offer valuable insights for developing targeted cancer therapies.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
MAGE-A Antibody (6C1) References:
- Mage-b4, a novel melanoma antigen (MAGE) gene specifically expressed during germ cell differentiation. | Osterlund, C., et al. 2000. Cancer Res. 60: 1054-61. PMID: 10706124
- A MAGE-A1 peptide is recognized on HLA-B7 human tumors by cytolytic T lymphocytes. | Luiten, R. and van der Bruggen, P. 2000. Tissue Antigens. 55: 149-52. PMID: 10746786
- Expression of MAGE, GAGE and BAGE genes in human liver diseases: utility as molecular markers for hepatocellular carcinoma. | Kobayashi, Y., et al. 2000. J Hepatol. 32: 612-7. PMID: 10782910
- Immunoreactivity with the anti-MAGE antibody 57B in malignant melanoma: frequency of expression and correlation with prognostic parameters. | Busam, KJ., et al. 2000. Mod Pathol. 13: 459-65. PMID: 10786815
- Comparative analysis of genetically modified dendritic cells and tumor cells as therapeutic cancer vaccines. | Klein, C., et al. 2000. J Exp Med. 191: 1699-708. PMID: 10811863
- Melanoma antigen genes 1 and 2 are differentially expressed in human gastric and cardial carcinomas. | Granelli, P., et al. 2000. Scand J Gastroenterol. 35: 528-33. PMID: 10868457
- Genetic detection for micrometastasis in lymph node of biliary tract carcinoma. | Okami, J., et al. 2000. Clin Cancer Res. 6: 2326-32. PMID: 10873083
- Expression of MAGE-A and NY-ESO-1 in Primary and Metastatic Cancers. | Park, TS., et al. 2016. J Immunother. 39: 1-7. PMID: 26641256
- MAGE-A is More Highly Expressed Than NY-ESO-1 in a Systematic Immunohistochemical Analysis of 3668 Cases. | Kerkar, SP., et al. 2016. J Immunother. 39: 181-7. PMID: 27070449
- Functional interaction between co-expressed MAGE-A proteins. | Laiseca, JE., et al. 2017. PLoS One. 12: e0178370. PMID: 28542476
- MAGE-A antigens as targets for cancer immunotherapy. | Schooten, E., et al. 2018. Cancer Treat Rev. 67: 54-62. PMID: 29763778
- Research progress in effects of MAGE-A family on gastric cancer. | Jia, Q., et al. 2023. Zhong Nan Da Xue Xue Bao Yi Xue Ban. 48: 260-267. PMID: 36999473
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MAGE-A Antibody (6C1) | sc-20034 | 200 µg/ml | $322.00 | |||
MAGE-A Antibody (6C1): m-IgGκ BP-HRP Bundle | sc-520710 | 200 µg Ab, 40 µg BP | $361.00 | |||
MAGE-A Antibody (6C1) AC | sc-20034 AC | 500 µg/ml, 25% agarose | $424.00 | |||
MAGE-A Antibody (6C1) HRP | sc-20034 HRP | 200 µg/ml | $322.00 | |||
MAGE-A Antibody (6C1) FITC | sc-20034 FITC | 200 µg/ml | $336.00 | |||
MAGE-A Antibody (6C1) PE | sc-20034 PE | 200 µg/ml | $349.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 488 | sc-20034 AF488 | 200 µg/ml | $364.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 546 | sc-20034 AF546 | 200 µg/ml | $364.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 594 | sc-20034 AF594 | 200 µg/ml | $364.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 647 | sc-20034 AF647 | 200 µg/ml | $364.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 680 | sc-20034 AF680 | 200 µg/ml | $364.00 | |||
MAGE-A Antibody (6C1) Alexa Fluor® 790 | sc-20034 AF790 | 200 µg/ml | $364.00 |